Healthcare Stocks Investor's Watch List - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Catabasis Pharmaceuticals
- Author: Zachary Reyes May 27, 2017,
May 27, 2017, 10:12
The Lower end of the earnings estimate is $-0.21, while the higher end of the earnings estimate is $-0.15.
Whereas they predicted High and Low Earnings Estimate as $-0.15 and $-0.21 respectively.
Shares of BioCryst Pharmaceuticals, Inc. The firm has "Sell" rating by Zacks given on Friday, August 7. The current consensus recommendation provided by covering analysts is 2.50. This is according to all covering research brokerage firms taken into consideration by First Call. The Scharf Investments Llc holds 5,706 shares with $972,000 value, down from 574,015 last quarter. However a year ago for the same quarter the company has reported $-0.22 EPS. Ameritas Investment Partners Inc. bought a new stake in Aerie Pharmaceuticals during the first quarter worth $108,000. Revenue during that quarter was posted at $0M, whereas the consensus estimate was predicting $0M. While in the same Quarter Previous year, the Actual EPS was $-0.22. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 75.08% since May 26, 2016 and is uptrending.
Several research analysts recently weighed in on BCRX shares. BCRX stock has more than doubled over the past 12 months, but it's still a favorite among short sellers. Needham & Company LLC restated a "hold" rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 12th. While past twelve months price to sales ratio recorded as 1.08 and price to cash ratio remained 7.69. Canaccord Genuity set a $56.00 price target on Aerie Pharmaceuticals and gave the stock a "buy" rating in a research report on Saturday, March 11th. Finally, Ladenburg Thalmann Financial Services initiated coverage on BioCryst Pharmaceuticals in a research report on Thursday, February 16th. Stock's intraday price range hit the peak level of $7.39 and touched the lowest level of $6.15.
Proofpoint, Inc. has a consensus outperform rating from 26 Wall Street analysts, and the number of shares now sold short amount to at least 18.34% of shares outstanding. According to Thomson Reuters, analysts are projecting a consensus target price of $8.63 on company shares.
TRADEMARK VIOLATION WARNING: This report was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of USA and global copyright & trademark law.
6 analysts on average are expecting BioCryst Pharmaceuticals, Inc.to report earnings of $-0.18 per share for the current quarter. It seems that BioCryst Pharmaceuticals, Inc. The company had a trading volume of 854,427 shares.
In taking a look at technical levels, shares are trading 27.82% away from the 50 day simple moving average and 43.37% away from the 200 day simple moving average. (NASDAQ:BCRX) concerning results from an interim analysis of the company's Phase 2 APeX-1 clinical trial for hereditary angioedema (HAE). The stock's market cap is $1.82 billion. The stock was sold at an average price of $8.43, for a total transaction of $54,795.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Kdi Capital Lc invested in 3.86% or 153,676 shares.
The stock has a 1-year performance up 100.90% and a positive weekly performance at 14.65%. The disclosure for this sale can be found here. When we divide the current volume by the three-month average volume, we get a relative volume of 14.92. Corporate insiders own 8.77% of the company's stock.
Private Bancorp Incorporated (NASDAQ:PVTB) had an increase of 9.98% in short interest. Highbridge Capital Management Ltd Liability Company owns 0.01% invested in Visa Inc (NYSE:V) for 9,196 shares. Mufg Americas Corp stated it has 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company's stock valued at $111,000 after buying an additional 45 shares during the period. Wells Fargo & Company MN raised its stake in BioCryst Pharmaceuticals by 29.8% in the third quarter.